On Tuesday, Shares of Louisiana-Pacific Corp. (NYSE:LPX), gained 5.40% to $17.18.
Louisiana-Pacific Corporation, stated results for the first quarter of 2015, which comprised of the following:
- Sales for the first quarter of $472 million were higher by 6 percent contrast to the year ago quarter.
- Loss from ongoing operations was $35 million ($0.24 per diluted share).
- Non-GAAP adjusted loss from ongoing operations was $19 million ($0.13 per diluted share).
- Adjusted EBITDA from ongoing operations for the first quarter was $6 million contrast to $23 million in the first quarter of 2014.
- Cash and cash equivalents were $468 million as of March 31, 2015.
Louisiana-Pacific Corporation, together with its auxiliaries, primarily manufactures and sells building products for use in new home construction, repair and remodeling, outdoor structures, and light industrial and commercial construction.
At the end of Tuesday’s trade, Shares of NewLink Genetics Corporation (NASDAQ:NLNK), jumped 5.28% to $47.02.
NewLink Genetics Corporation, stated merged financial results for the first quarter of 2015 and progress in its clinical and business development programs.
HyperAcute(R) Cancer Immunotherapy Programs
- NewLink Genetics’ proprietary cancer immuno-oncology programs may prove to have broad potential across a spectrum of cancer indications, counting in combination with checkpoint inhibitors. NewLink Genetics has multiple HyperAcute immunotherapy programs in various stages of clinical development, counting pancreatic cancer, lung cancer, and melanoma.
- Algenpantucel-L is NewLink Genetics’ HyperAcute pancreatic cancer immunotherapy candidate in a Phase 3 clinical trial called, IMmunotherapy for Pancreatic RESectable cancerStudy, or IMPRESS. The study, evaluating the addition of algenpantucel-L to standard of care therapy after surgery for pancreatic cancer, is fully enrolled and the second interim analysis is predictable to be stated in the second quarter of 2015.
- PILLAR, or Pancreatic Immunotherapy with algenpantucel-L for Locally Advanced non-Resectable disease is our Phase 3 clinical trial studying the efficacy of algenpantucel-L in patients with locally advanced pancreatic cancer. The Company continues to expect to complete enrollment in the second half of 2015.
- Tergenpumatucel-L for patients with lung cancer is NewLink Genetics’ HyperAcute lung immunotherapy being tested in a randomized, Phase 2b study in advanced lung cancer. An update on this program will be offered in the second half of 2015.
- Dorgenmeltucel-L for patients with melanoma is being evaluated in a randomized Phase 2 study in combination with ipilimumab vs. ipilimumab alone.
NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance treatment options for patients with cancer.
Integrated Device Technology, Inc. (NASDAQ:IDTI), ended its last trade with 5.17% gain, and closed at $19.32.
Integrated Device Technology, declared results for the fiscal fourth quarter and fiscal year ended March 29, 2015.
Recent Business Highlights - Communications
- IDT Introduces Ultra-Low-Jitter Family of LVCMOS Clock Buffers
- IDT Surpasses 10 Million RFIC Shipments
- IDT Introduces High-Performance Crystal Oscillators with Best-in-Class Jitter Performance, Low Cost and Short Production Lead Times.
Recent Business Highlights - Consumer
- IKEA Furniture Features IDT Wireless Charging
- IDT’s Latest Wireless Power Receiver Brings Faster Charging Through Higher Efficiency
- IDT Wireless Power Transmitter Adopted for Samsung Galaxy
- IDT Introduces Wireless PowerShare Technology, Enabling Mobile Devices to Wirelessly Charge One Another
- New IDT Wireless Power Chipset Untethers Tablets and Phablets.
Integrated Device Technology, Inc. designs, develops, manufactures, and markets a range of mixed signal semiconductor solutions for the communications, computing, and consumer industries worldwide.
Finally, UBS Group AG (NYSE:UBS), closed at $21.37, with 4.96% gain, hitting its highest level.
All UB’s businesses navigated the extraordinary challenges of the first quarter well. This was reflected in a Group adjusted profit before tax of CHF 2.3 billion, a very strong result, particularly considering the extreme volatility in foreign exchange rates, currency translation effects and the continued impact of low to negative interest rates on its businesses. UBS stated net profit attributable to shareholders of CHF 1,977 million and diluted earnings per share of CHF 0.53. The quarter showed that clients value UBS’s advice and the firm is succeeding in the areas in which it chooses to compete.
Business division highlights
- Combined wealth administration businesses adjusted profit before tax CHF 1.1 billion, the highest since 2008; net new money CHF 19 billion
- Wealth Administration adjusted profit before tax CHF 856 million; net new money very strong at CHF 14.4 billion, taking the annualized net new money growth rate above the target range; adjusted1 cost / income ratio improved and was within the target range
- Wealth Administration Americas adjusted profit before tax USD 293 million, another quarterly record; net new money USD 4.8 billion, taking the annualized net new money growth rate slightly below the target range; adjusted1 cost / income ratio improved and was within the target range
- Retail & Corporate adjusted profit before tax CHF 443 million, the best first-quarter result in five years; annualized net new business volume growth rate, net interest margin and adjusted1 cost / income ratio all improved and were within the target ranges
- Global Asset Administration adjusted profit before tax CHF 186 million; not taking into account money market flows, net new money inflows very strong at CHF 7.5 billion; annualized net new money growth rate, not taking into account money market flows, and cost / income ratio both improved and were within the target ranges
- Investment Bank adjusted profit before tax CHF 844 million; adjusted annualized return on attributed equity above target; adjusted1 cost / income ratio improved and was below the target range.
UBS Group AG, together with its auxiliaries, provides wealth administration, retail and corporate, asset administration, and investment banking products and services worldwide. The company’s Wealth Administration division provides financial services to wealthy private clients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
